An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
NCT ID: NCT01480674
Last Updated: 2017-08-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
160 participants
OBSERVATIONAL
2011-03-28
2012-11-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
NCT00475670
An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
NCT01332981
A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer
NCT00885755
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer
NCT02015676
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years
NCT01810393
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Trastuzumab
Eligible participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic or locally advanced breast cancer, who were treated with trastuzumab as a first-line therapy and were progression-free for at least 3 years after treatment initiation, were included and were followed for one year.
Trastuzumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trastuzumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HER2-positive metastatic breast cancer or locally advanced breast cancer
* Systemic treatment included Herceptin as 1st line therapy
* Without progression for at least 3 years after the beginning of Herceptin treatment
* Alive or not alive and treated or not treated with Herceptin at the time of inclusion
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique Du Docteur Calabet; Cromg
Agen, , France
C.H. Du Pays D'aix En Provence Service du Dr Blanc
Aix-en-Provence, , France
Poly Parc Rambot La Provencale; Chimiotherapie Ambulatoire
Aix-en-Provence, , France
Chd Castelluccio; Oncologie
Ajaccio, , France
Clinique De L Europe; Pmsi
Amiens, , France
Clinique De L Europe; Radiotherapie Chimiotherapie
Amiens, , France
HOP Prive Arras Les Bonnettes; Chimiotherapie
Arras, , France
Hopital Europeen La Roseraie;Radiotherapie
Aubervilliers, , France
Polyclinique Sainte Marguerite; Chimiotherapie
Auxerre, , France
Clinique Champeau Mediterranee; Radiotherapie Oncologie
Béziers, , France
Hopital Saint Andre; Oncologie 2
Bordeaux, , France
Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie
Bordeaux, , France
Centre Hospitalier Fleyriat; Oncologie/Hematologie
Bourg-en-Bresse, , France
Hopital Augustin Morvan; Hopital De Jour
Brest, , France
Ch De Brive La Gaillarde; Radiotherapie Oncologie
Brive-la-Gaillarde, , France
Centre Francois Baclesse; Comite Sein
Caen, , France
Ch Antoine Gayraud; Oncologie
Carcassonne, , France
Clinique Montreal; Chimiotherapie
Carcassonne, , France
Ch William Morey; Medecine 1
Chalon-sur-Saône, , France
Centre Jean Perrin; Hopital De Jour
Clermont-Ferrand, , France
Pole Sante Republique;Oncologie Hematologie
Clermont-Ferrand, , France
Ch De Dax; Radiotherapie Oncologie
Dax, , France
Centre Leonard De Vinci;Chimiotherapie
Dechy, , France
Centre Georges Francois Leclerc; Oncologie 3
Dijon, , France
Hopital Prive Drome Ardeche; Chir 2A 2B
Guilherand-Granges, , France
Clinique de L' Esperance; Oncologie
Hyères, , France
Polyclinique de Blois; Chimiotherapie Ambulatoire
La Chaussée-Saint-Victor, , France
CH Dptal Les Oudairies; Hematologie Oncologie
La Roche-sur-Yon, , France
Hopital Albert Michallon; Oncologie
La Tronche, , France
Polyclinique Du Bois; Centre Bourgogne
Lille, , France
Polyclinique Du Bois; Oncologie
Lille, , France
Ch De Longjumeau; Hopital De Jour Et Semaine
Longjumeau, , France
Clinique Des 4 Pavillons; Chimiotherapie
Lormont, , France
Centre Leon Berard; Departement Oncologie Medicale
Lyon, , France
Polyclinique Du Beaujolais; Chimiotherapie
Lyon, , France
Hopital Edouard Herriot; Pavillon F Rhumatologie
Lyon, , France
Hôpital Saint Joseph; Oncologie Medicale
Marseille, , France
Polyclinique Du Val De Saone; Chimiotherapie
Mâcon, , France
Ch De Montelimar; Radiotherapie
Montélimar, , France
Clinique Clementville; Hopital De Jour
Montpellier, , France
Polyclinique Saint Roch; Hop Jour Chimio Radiotherapie
Montpellier, , France
Centre Azureen De Cancerologie; Cons externes
Mougins, , France
Hopital Emile Muller; Oncologie Radiotherapie
Mulhouse, , France
Centre D'Oncologie de Gentilly; Oncology
Nancy, , France
Polyclinique Gentilly; CHIMIOTHERAPIE AMBULATOIRE
Nancy, , France
Clinique Des Genets; Radiotherapie
Narbonne, , France
Clinique Henry Hartmann; Oncologie
Neuilly-sur-Seine, , France
Centre Antoine Lacassagne; Hopital De Jour A2
Nice, , France
Centre Hospitalier Uni Ire Caremeau; Radiotherapie & Oncologie
Nîmes, , France
Polyclinique Kenval ; Radiotherapie Oncologie
Nîmes, , France
Clinique sainte marie; chimiotherapie ambulatoire
Osny, , France
Hopital Saint Louis; Oncologie Medicale
Paris, , France
Hopital Des Diaconesses; Hopital De Jour
Paris, , France
Ch Pitie Salpetriere; Oncologie Medicale
Paris, , France
HOPITAL TENON; Cancerologie Medicale
Paris, , France
Clinique Francheville; Radiotherapie
Périgueux, , France
Ch Lyon Sud; Hemato Secteur Jules Courmont
Pierre-Bénite, , France
Ch Lyon Sud; Onco Secteur Jules Courmont
Pierre-Bénite, , France
Ch De Pithiviers; Consult Externes
Pithiviers, , France
Institut Jean Godinot; Pavillon Rubis
Reims, , France
Polyclinique De Courlancy; Chimiotherapie Ambulatoire
Reims, , France
Centre Eugene Marquis; Unite Huguenin
Rennes, , France
Clinique Saint Hilaire; Sce Chimiotherapie
Rouen, , France
Chp Saint Gregoire; Cancerologie Radiotherapie
Saint-Grégoire, , France
Ico Rene Gauducheau; Oncologie
Saint-Herblain, , France
Clinique de L'Union; Oncologie
Saint-Jean, , France
Centre Radiotherapie Etienne Dolet
Saint-Nazaire, , France
Institut De Cancerologie De La Loire; Consult Oncologie Niveau 0
Saint-Priest-en-Jarez, , France
Ch De Saint Quentin; Medecine B10
Saint-Quentin, , France
CH De Senlis; Medecine 2
Senlis, , France
Ch De Soissons; Medecine Ambulatoire
Soissons, , France
Institut Claudius Regaud; Departement Oncologie Medicale
Toulouse, , France
Clinique Pasteur; Oncologie Medicale
Toulouse, , France
Chevelle Christian; Centre De Radiotherapie
Toulouse, , France
Centre Alexis Vautrin; Oncologie Medicale
Vandœuvre-lès-Nancy, , France
Hopital Saint Nicolas; Pneumologie
Verdun, , France
Institut Gustave Roussy; Comite 5
Villejuif, , France
Institut Gustave Roussy; Departement Oncologie Medicale
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML23001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.